Literature DB >> 17950367

Expression of VACM-1/cul5 mutant in endothelial cells induces MAPK phosphorylation and maspin degradation and converts cells to the angiogenic phenotype.

A Buchwalter1, C Van Dort, S Schultz, R Smith, I P Le, J L Abbott, E Oosterhouse, A E Johnson, F Hansen-Smith, M Burnatowska-Hledin.   

Abstract

Vasopressin-activated calcium mobilizing receptor (VACM-1) is a member of the cullin gene family involved in ubiquitin-proteosome dependent regulation of cellular functions. Expression of VACM-1 cDNA in cos-1 cells in vitro decreases basal cAMP levels and inhibits growth. The expression of (S730A)VACM-1 mutant cDNA, which removes PKA-dependent phosphorylation site in the VACM-1 cDNA sequence, reverses this phenotype. Since the expression of VACM-1 protein in vivo localizes largely to the vascular endothelial cells, in this study, we examined the effects of (S730A)VACM-1 cDNA expression on cellular signaling in the rat endothelial cell line RAMEC. Our results indicate that expression of (S730A)VACM-1 cDNA in RAMEC promotes cellular proliferation and induces angiogenic growth patterns. Western blot analyses indicate that (S730A)VACM-1 cDNA transfected cells express increased levels of Nedd8 modified VACM-1 and have higher levels of phosphorylated MAPK protein when compared to controls. Furthermore, expression of (S730A)VACM-1 cDNA induces translocation of the endogenous early response gene, egr-1, to the nucleus and leads to morphological changes that involve actin rearrangement. Finally, expression of (S730A)VACM-1 cDNA in RAMEC decreases concentration of maspin, a putative anti-angiogenic factor with a tumor suppressor activity. These results show that VACM-1 protein regulates endothelial cell growth and may modulate angiogenesis by a mechanism that involves MAPK phosphorylation, nuclear localization of egr-1, maspin expression, and actin polymerization.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17950367     DOI: 10.1016/j.mvr.2007.08.004

Source DB:  PubMed          Journal:  Microvasc Res        ISSN: 0026-2862            Impact factor:   3.514


  7 in total

Review 1.  Vasopressin: the missing link for preeclampsia?

Authors:  Jeremy A Sandgren; Sabrina M Scroggins; Donna A Santillan; Eric J Devor; Katherine N Gibson-Corley; Gary L Pierce; Curt D Sigmund; Mark K Santillan; Justin L Grobe
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2015-03-25       Impact factor: 3.619

2.  Bone marrow mesenchymal stem cells combined with minocycline improve spinal cord injury in a rat model.

Authors:  Dayong Chen; Wei Zeng; Yunfeng Fu; Meng Gao; Guohua Lv
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

3.  Phosphorylation of VACM-1/Cul5 by protein kinase A regulates its neddylation and antiproliferative effect.

Authors:  Shirley E Bradley; Alyssa E Johnson; Isabelle P Le; Elizabeth Oosterhouse; Michael P Hledin; Gabriel A Marquez; Maria Burnatowska-Hledin
Journal:  J Biol Chem       Date:  2009-11-16       Impact factor: 5.157

4.  SENP8 limits aberrant neddylation of NEDD8 pathway components to promote cullin-RING ubiquitin ligase function.

Authors:  Kate E Coleman; Miklós Békés; Jessica R Chapman; Sarah B Crist; Mathew Jk Jones; Beatrix M Ueberheide; Tony T Huang
Journal:  Elife       Date:  2017-05-05       Impact factor: 8.140

5.  The CUL3-SPOP-DAXX axis is a novel regulator of VEGFR2 expression in vascular endothelial cells.

Authors:  Tomohisa Sakaue; Iori Sakakibara; Takahiro Uesugi; Ayako Fujisaki; Koh-Ichi Nakashiro; Hiroyuki Hamakawa; Eiji Kubota; Takashi Joh; Yuuki Imai; Hironori Izutani; Shigeki Higashiyama
Journal:  Sci Rep       Date:  2017-02-20       Impact factor: 4.379

Review 6.  The role of cullin 5-containing ubiquitin ligases.

Authors:  Fumihiko Okumura; Akiko Joo-Okumura; Kunio Nakatsukasa; Takumi Kamura
Journal:  Cell Div       Date:  2016-03-09       Impact factor: 5.130

7.  CUL5 is required for thalidomide-dependent inhibition of cellular proliferation.

Authors:  Bryan Kunkler; Daniel Salamango; Zachary J DeBruine; Caitlin Ploch; Shirley Dean; David Grossens; Michael P Hledin; Gabriel A Marquez; Julie Madden; Abigayle Schnell; Michael Short; Maria A Burnatowska-Hledin
Journal:  PLoS One       Date:  2018-05-10       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.